论文部分内容阅读
目的比较瑞舒伐他汀与阿托伐他汀对冠心病患者血脂的临床治疗效果。方法选择我院2014年6月—2015年2月科室收治的98例冠心病血脂患者,按照患者自愿原则,将患者分为观察组与对照组,每组49例。观察组患者口服瑞舒伐他汀钙(10 mg/片),对照组患者口服阿托伐他汀钙片(10 mg/片)。4周为一个疗程,连续治疗3个疗程后比较两组血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(低密度脂蛋白胆固醇)(LDL-C)达标率以及治疗前、治疗后TC、TG、LDL-C以及高密度脂蛋白(高密度脂蛋白胆固醇)(HDL-C)水平的变化。结果观察组患者的TC、TG及LDL-C达标率分别为69.39%(34/49)、71.43%(35/49)、83.67%(41/49),与对照组患者46.94%(23/49)、53.06%(26/49)、61.22%(30/49)比较差异有统计学意义(P均<0.05);治疗前后观察组患者TC、TG、LDL-C水平显著低于对照组,差异有统计学意义(P<0.05),HDL-C变化水平2组治疗前后差异无统计学意义(P>0.05)。结论与阿托伐他汀比较,瑞舒伐他汀在改善冠心病患者TC、TG、LDL-C方面具有显著疗效,在改善HDL-C方面无优越性。
Objective To compare the clinical effects of rosuvastatin and atorvastatin on blood lipids in patients with coronary heart disease. Methods Ninety-eight patients with coronary heart disease were selected from our department from June 2014 to February 2015. Patients were divided into observation group and control group according to the voluntary principle of patients, with 49 cases in each group. Patients in the observation group were given oral rosuvastatin calcium (10 mg / tablet), and patients in the control group were given atorvastatin calcium tablets (10 mg / tablet). 4 weeks for a course of treatment, continuous treatment of three courses of treatment after the two groups compared the level of serum total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C) compliance rate and before treatment , TC, TG, LDL-C and HDL-C levels after treatment. Results The compliance rates of TC, TG and LDL-C in the observation group were 69.39% (34/49), 71.43% (35/49) and 83.67% (41/49), respectively, which were significantly lower than those in the control group (46.94%, 23/49 ), 53.06% (26/49) and 61.22% (30/49), respectively (all P <0.05). The levels of TC, TG and LDL-C in the observation group before and after treatment were significantly lower than those in the control group (P <0.05). There was no significant difference in HDL-C level between the two groups before and after treatment (P> 0.05). Conclusions Compared with atorvastatin, rosuvastatin has a significant effect in improving TC, TG and LDL-C in patients with coronary heart disease, and there is no superiority in improving HDL-C.